Regulatory T cells (Tregs) are essential for controlling peripheral tolerance by the active suppression of various immune cells including conventional T effector cells (Teffs). Downstream of the T cell receptor (TCR), more than 500 protein kinases encoded by the human genome have to be considered in signaling cascades regulating the activation of Tregs and Teffs, respectively. Following TCR engagement, Tregs posses a number of unique attributes, such as constitutive expression of Foxp3, hyporesponsiveness and poor cytokine production. Furthermore, recent studies showed that altered regulation of protein kinases is important for Treg function. These data indicate that signaling pathways in Tregs are distinctly organized and alterations at the level of protein kinases contribute to the unique Treg phenotype. However, kinase-based signaling networks in Tregs are poorly understood and necessitate further systematic characterization. In this study, we analyzed the differential expression of kinases in Tregs and Teffs by using a kinase-selective proteome strategy. In total, we revealed quantitative information on 185 kinases expressed in the human CD4+ T cell subsets. The majority of kinases was equally abundant in both T cell subsets, but 11 kinases were differentially expressed in Tregs. Most strikingly, Tregs showed an altered expression of cell cycle kinases including CDK6. Quantitative proteomics generates first comparative insight into the kinase complements of the CD4+ Teff and Treg subset. Treg-specific expression pattern of 11 protein kinases substantiate the current opinion that TCR-mediated signaling cascades are altered in Tregs and further suggests that Tregs exhibit significant specificities in cell-cycle control and progression.
References
[1]
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8–27.
[2]
Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352.
[3]
Shevach EM (2004) Regulatory/suppressor T cells in health and disease. Arthritis Rheum 50: 2721–2724.
[4]
Belkaid Y, Sun CM, Bouladoux N (2006) Parasites and immunoregulatory T cells. Curr Opin Immunol 18: 406–412.
[5]
Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457–462.
[6]
Tai X, Cowan M, Feigenbaum L, Singer A (2005) CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 6: 152–162.
[7]
Vang KB, Yang J, Pagan AJ, Li LX, Wang J, et al. Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development. J Immunol 184: 4074–4077.
[8]
Kim JK, Klinger M, Benjamin J, Xiao Y, Erle DJ, et al. (2009) Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking. PLoS One 4: e6580.
[9]
Gupta S, Manicassamy S, Vasu C, Kumar A, Shang W, et al. (2008) Differential requirement of PKC-theta in the development and function of natural regulatory T cells. Mol Immunol 46: 213–224.
[10]
Huehn J, Polansky JK, Hamann A (2009) Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 9: 83–89.
[11]
Cantrell DA (2002) T-cell antigen receptor signal transduction. Immunology 105: 369–374.
[12]
Acuto O, Di Bartolo V, Micheli F (2008) Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol 8: 699–712.
[13]
Li L, Godfrey WR, Porter SB, Ge Y, June CH, et al. (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106: 3068–3073.
[14]
Hickman SP, Yang J, Thomas RM, Wells AD, Turka LA (2006) Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells. J Immunol 177: 2186–2194.
[15]
Su L, Creusot RJ, Gallo EM, Chan SM, Utz PJ, et al. (2004) Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol 173: 4994–5001.
[16]
Levings MK, Sangregorio R, Roncarolo MG (2001) Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193: 1295–1302.
[17]
Tsang JY, Camara NO, Eren E, Schneider H, Rudd C, et al. (2006) Altered proximal T cell receptor (TCR) signaling in human CD4+CD25+ regulatory T cells. J Leukoc Biol 80: 145–151.
[18]
Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, et al. (2004) Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 172: 5287–5296.
[19]
Crellin NK, Garcia RV, Levings MK (2007) Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109: 2014–2022.
[20]
Graham JA, Fray M, de Haseth S, Lee KM, Lian MM, et al. (2010) Suppressive regulatory T cell activity is potentiated by glycogen synthase kinase 3{beta} inhibition. J Biol Chem 285: 32852–32859.
[21]
Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 328: 372–376.
[22]
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1934.
[23]
Ocklenburg F, Moharregh-Khiabani D, Geffers R, Janke V, Pfoertner S, et al. (2006) UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells. Lab Invest 86: 724–737.
[24]
Pfoertner S, Jeron A, Probst-Kepper M, Guzman CA, Hansen W, et al. (2006) Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol 7: R54.
[25]
Probst-Kepper M, Geffers R, Kroger A, Viegas N, Erck C, et al. (2009) GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med 13(9B): 3343–57.
[26]
McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, et al. (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311–323.
[27]
Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, et al. (2004) Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 34: 623–630.
[28]
Feuerer M, Hill JA, Kretschmer K, von Boehmer H, Mathis D, et al. (2010) Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci U S A 107: 5919–5924.
[29]
Kubach J, Lutter P, Bopp T, Stoll S, Becker C, et al. (2007) Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110: 1550–1558.
[30]
Solstad T, Bains SJ, Landskron J, Aandahl EM, Thiede B, et al. (2011) CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. Blood 118: 5141–5151.
[31]
Reinl T, Nimtz M, Hundertmark C, Johl T, Keri G, et al. (2009) Quantitative phosphokinome analysis of the Met pathway activated by the invasin InlB from listeria monocytogenes. Mol Cell Proteomics 8(12): 2778–95.
[32]
Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31: 438–448.
[33]
Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6: 537–547.
[34]
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035–1044.
[35]
Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8: 1751–1764.
[36]
Konig S, Nimtz M, Scheiter M, Ljunggren HG, Bryceson YT, et al. (2012) Kinome analysis of receptor-induced phosphorylation in human natural killer cells. PLoS One 7: e29672.
[37]
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490–500.
[38]
Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, et al. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol 7: 411–422.
[39]
Becker F, Murthi K, Smith C, Come J, Costa-Roldan N, et al. (2004) A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem Biol 11: 211–223.
[40]
Hundertmark C, Fischer R, Reinl T, May S, Klawonn F, et al. (2009) MS-specific noise model reveals the potential of iTRAQ in quantitative proteomics. Bioinformatics 25: 1004–1011.
[41]
Hughes K, Edin S, Antonsson A, Grundstrom T (2001) Calmodulin-dependent kinase II mediates T cell receptor/CD3- and phorbol ester-induced activation of IkappaB kinase. J Biol Chem 276: 36008–36013.
[42]
Ishiguro K, Green T, Rapley J, Wachtel H, Giallourakis C, et al. (2006) Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation. Mol Cell Biol 26: 5497–5508.
[43]
Ishiguro K, Ando T, Goto H, Xavier R (2007) Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II. Mol Immunol 44: 2095–2100.
[44]
Branch DR, Mills GB (1995) pp60c-src expression is induced by activation of normal human T lymphocytes. J Immunol 154: 3678–3685.
[45]
Couture C, Songyang Z, Jascur T, Williams S, Tailor P, et al. (1996) Regulation of the Lck SH2 domain by tyrosine phosphorylation. J Biol Chem 271: 24880–24884.
[46]
Song J, Salek-Ardakani S, So T, Croft M (2007) The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 8: 64–73.
[47]
Song J, Lei FT, Xiong X, Haque R (2008) Intracellular signals of T cell costimulation. Cell Mol Immunol 5: 239–247.
[48]
Song J, So T, Croft M (2008) Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 180: 7240–7248.
[49]
Tao L, Wadsworth S, Mercer J, Mueller C, Lynn K, et al. (2002) Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells. Biochem J 363: 175–182.
[50]
Endo J, Toyama-Sorimachi N, Taya C, Kuramochi-Miyagawa S, Nagata K, et al. (2000) Deficiency of a STE20/PAK family kinase LOK leads to the acceleration of LFA-1 clustering and cell adhesion of activated lymphocytes. FEBS Lett 468: 234–238.
[51]
Katagiri K, Imamura M, Kinashi T (2006) Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol 7: 919–928.
[52]
Sharfe N, Nikolic M, Cimpeon L, Van De Kratts A, Freywald A, et al. (2008) EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol Immunol 45: 1208–1220.
[53]
Yu G, Luo H, Wu Y, Wu J (2004) EphrinB1 is essential in T-cell-T-cell co-operation during T-cell activation. J Biol Chem 279: 55531–55539.
[54]
Yu G, Mao J, Wu Y, Luo H, Wu J (2006) Ephrin-B1 is critical in T-cell development. J Biol Chem 281: 10222–10229.
[55]
Alfaro D, Garcia-Ceca JJ, Cejalvo T, Jimenez E, Jenkinson EJ, et al. (2007) EphrinB1-EphB signaling regulates thymocyte-epithelium interactions involved in functional T cell development. Eur J Immunol 37: 2596–2605.
[56]
Alfaro D, Munoz JJ, Garcia-Ceca J, Cejalvo T, Jimenez E, et al. (2008) Alterations in the thymocyte phenotype of EphB-deficient mice largely affect the double negative cell compartment. Immunology 125: 131–143.
[57]
Munoz JJ, Alfaro D, Garcia-Ceca J, Alonso CL, Jimenez E, et al. (2006) Thymic alterations in EphA4-deficient mice. J Immunol 177: 804–813.
[58]
Munoz JJ, Garcia-Ceca J, Alfaro D, Stimamiglio MA, Cejalvo T, et al. (2009) Organizing the thymus gland. Ann N Y Acad Sci 1153: 14–19.
[59]
Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, et al. (2002) Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99: 4465–4470.
[60]
Saez-Rodriguez J, Simeoni L, Lindquist JA, Hemenway R, Bommhardt U, et al. (2007) A logical model provides insights into T cell receptor signaling. PLoS Comput Biol 3: e163.
[61]
Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, et al. (2009) Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J 28: 1319–1331.
[62]
Kitamura T, Kabuyama Y, Kamataki A, Homma MK, Kobayashi H, et al. (2008) Enhancement of lymphocyte migration and cytokine production by ephrinB1 system in rheumatoid arthritis. Am J Physiol Cell Physiol 294: C189–196.
[63]
Holen HL, Nustad K, Aasheim HC Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration. J Leukoc Biol 87: 1059–1068.
[64]
Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A (2002) Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3: 33–41.
[65]
Eitelhuber AC, Warth S, Schimmack G, Duwel M, Hadian K, et al. (2011) Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation. EMBO J 30: 594–605.
[66]
Long M, Park SG, Strickland I, Hayden MS, Ghosh S (2009) Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 31: 921–931.
[67]
Hori S (2010) c-Rel: a pioneer in directing regulatory T-cell lineage commitment? Eur J Immunol 40: 664–667.
[68]
Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, et al. (2000) p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6: 290–297.
[69]
Toda A, Piccirillo CA (2006) Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leukoc Biol 80: 458–470.
[70]
Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA (2002) CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 168: 2729–2736.
[71]
Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA (2000) CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 164: 144–151.
[72]
Grossel MJ, Baker GL, Hinds PW (1999) cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J Biol Chem 274: 29960–29967.
[73]
Reed SI (1997) Control of the G1/S transition. Cancer Surv 29: 7–23.
[74]
Boonen GJ, van Dijk AM, Verdonck LF, van Lier RA, Rijksen G, et al. (1999) CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes. Eur J Immunol 29: 789–798.
[75]
Kovalev GI, Franklin DS, Coffield VM, Xiong Y, Su L (2001) An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol 167: 3285–3292.
[76]
Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, et al. (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493–504.
[77]
Yang Z, Cao Y, Zhu X, Huang Y, Ding Y, et al. (2009) Znhit1 causes cell cycle arrest and down-regulates CDK6 expression. Biochem Biophys Res Commun 386: 146–152.
[78]
Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI, Nerlov C (2007) Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J 26: 2361–2370.
[79]
Kitoh A, Ono M, Naoe Y, Ohkura N, Yamaguchi T, et al. (2009) Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 31: 609–620.
[80]
Zhang L, Fried FB, Guo H, Friedman AD (2008) Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111: 1193–1200.
[81]
Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE (2006) AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol 26: 7420–7429.
[82]
Hancock WW, Ozkaynak E (2009) Three distinct domains contribute to nuclear transport of murine Foxp3. PLoS One 4: e7890.
[83]
Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, et al. (2009) Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med 206: 2701–2715.
[84]
Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. (2007) Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446: 685–689.
[85]
Zhang F, Meng G, Strober W (2008) Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 9: 1297–1306.
[86]
Bruno L, Mazzarella L, Hoogenkamp M, Hertweck A, Cobb BS, et al. (2009) Runx proteins regulate Foxp3 expression. J Exp Med 206: 2329–2337.
[87]
Goh YM, Cinghu S, Hong ET, Lee YS, Kim JH, et al. Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J Biol Chem 285: 10122–10129.
[88]
Wessel D, Flugge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141–143.
